The invention relates to provide a fermented milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 0.9 mg/100 g to 150 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.

The invention relates to provide a fermented milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 0.9 mg/100 g to 150 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.

The present invention relates to a collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from peptides of which at least 50% by weight, in particular at least 70% by weight have a molecular weight of 1,500 Da to 3,500 Da, and which have a mean molecular weight in the range from 4,000 Da to 8,000 Da, in particular in the range from 4,500 Da to 6,000 Da. The invention also relates to the use of this collagen hydrolysate as an active ingredient to maintain and/or improve the health of the bones, in particular to prevent and/or treat osteoporosis. The invention further relates to a nutritional supplement which comprises the collagen hydrolysate.

The present invention relates to a collagen hydrolysate which is produced by enzymatic hydrolysis of type-B bone gelatin, wherein the collagen hydrolysate is formed from peptides of which at least 50% by weight, in particular at least 70% by weight have a molecular weight of 1,500 Da to 3,500 Da, and which have a mean molecular weight in the range from 4,000 Da to 8,000 Da, in particular in the range from 4,500 Da to 6,000 Da. The invention also relates to the use of this collagen hydrolysate as an active ingredient to maintain and/or improve the health of the bones, in particular to prevent and/or treat osteoporosis. The invention further relates to a nutritional supplement which comprises the collagen hydrolysate.

An inventive nutritional supplement for increased Ca absorption is disclosed. The inventive nutritional supplement incorporates Ca in combination with specified amounts of L-Arginine and L-Lysine. The inventive nutritional supplement may also include Copper, Zinc, Manganese and Vitamin D3 as specified herein.

An inventive nutritional supplement for increased Ca absorption is disclosed. The inventive nutritional supplement incorporates Ca in combination with specified amounts of L-Arginine and L-Lysine. The inventive nutritional supplement may also include Copper, Zinc, Manganese and Vitamin D3 as specified herein.

Compositions containing apoaequorin and vitamin D and methods for their use in treating symptoms and disorders related to calcium imbalances and vitamin D deficiency associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention.

Compositions containing apoaequorin and vitamin D and methods for their use in treating symptoms and disorders related to calcium imbalances and vitamin D deficiency associated with, for example, sleep quality, energy quality, mood quality, memory quality or pain are provided by the present invention.

The present disclosure relates to a compound having the activity of promoting osteoblast differentiation and inhibiting adipocyte differentiation and a preparation method thereof. The novel compound of the present disclosure increases the expression of the gene ALP involved in the differentiation of osteoblasts, regulates expression of the genes PPAR, aP2 and CD36 involved in the differentiation of adipocytes, increases bone mineral density (BMD) in an ovariectomized osteoporosis animal model and decreases adipocytes in the bone marrow. Therefore, it can be used as an active ingredient of a medication or a health functional food useful for metabolic bone disease or obesity.

The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strains capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.